## Asa Karlsdottir

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9673600/publications.pdf

Version: 2024-02-01

840776 888059 18 373 11 17 citations h-index g-index papers 18 18 18 474 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Unilateral or Bilateral Retroperitoneal Lymph Node Dissection in Nonseminoma Patients with Postchemotherapy Residual Tumour? Results from RETROP, a Population-based Mapping Study by the Swedish Norwegian Testicular Cancer Group. European Urology Oncology, 2022, 5, 235-243.	5.4	11
2	Basosquamous Basal Cell Carcinoma with Bone Marrow Metastasis. Current Oncology, 2022, 29, 2193-2198.	2.2	O
3	Late relapses in testicular cancer: Results from a national cohort Journal of Clinical Oncology, 2022, 40, 5008-5008.	1.6	3
4	Metachronous Contralateral Testicular Cancer in the Cisplatin Era: A Population-Based Cohort Study. Journal of Clinical Oncology, 2021, 39, 308-318.	1.6	13
5	Testicular cancer in the cisplatin era: Causes of death and mortality rates in a population-based cohort Journal of Clinical Oncology, 2021, 39, 5006-5006.	1.6	3
6	Testicular Cancer in the Cisplatin Era: Causes of Death and Mortality Rates in a Population-Based Cohort. Journal of Clinical Oncology, 2021, 39, 3561-3573.	1.6	46
7	Serum miR371 in testicular germ cell cancer before and after orchiectomy, assessed by digital-droplet PCR in a prospective study. Scientific Reports, 2021, 11, 15582.	3.3	19
8	Surgical Complications in Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumour: A Population-based Study from the Swedish Norwegian Testicular Cancer Group. European Urology Oncology, 2020, 3, 382-389.	5.4	28
9	Continuing increased risk of second cancer in longâ€term testicular cancer survivors after treatment in the cisplatin era. International Journal of Cancer, 2020, 147, 21-32.	5.1	41
10	Ten-Year Results From a Phase II Study on Image Guided, Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost in High-Risk Prostate Cancer. Advances in Radiation Oncology, 2020, 5, 396-403.	1.2	11
11	Characteristics and prognosis of primary treatment-na $\tilde{A}$ -ve oral cavity squamous cell carcinoma in Norway, a descriptive retrospective study. PLoS ONE, 2020, 15, e0227738.	2.5	19
12	Quantitative PCR Measurement of miR-371a-3p and miR-372-p Is Influenced by Hemolysis. Frontiers in Genetics, 2019, 10, 463.	2.3	28
13	Inter-institutional analysis demonstrates the importance of lower than previously anticipated dose regions to prevent late rectal bleeding following prostate radiotherapy. Radiotherapy and Oncology, 2018, 127, 88-95.	0.6	14
14	Primary surgery results in no survival benefit compared to primary radiation for oropharyngeal cancer patients stratified by high-risk human papilloma virus status. European Archives of Oto-Rhino-Laryngology, 2017, 274, 477-487.	1.6	17
15	The ABC-study: A randomized phase III study comparing one course of adjuvant bleomycin, etoposide, and cisplatin (BEP) and one course of carboplatin AUC7 in clinical stage I seminomatous testicular cancer Journal of Clinical Oncology, 2017, 35, TPS4593-TPS4593.	1.6	2
16	Late Gastrointestinal Morbidity After Three-Dimensional Conformal Radiation Therapy for Prostate Cancer Fades With Time in Contrast to Genitourinary Morbidity. International Journal of Radiation Oncology Biology Physics, 2008, 70, 1478-1486.	0.8	44
17	Radiation dose escalation combined with hormone therapy improves outcome in localised prostate cancer. Acta Oncol $ ilde{A}^3$ gica, 2006, 45, 454-462.	1.8	7
18	Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer. Radiotherapy and Oncology, 2004, 71, 43-53.	0.6	67